$-0.28 EPS Expected for Oramed Pharmaceuticals Inc. (ORMP)

November 11, 2018 - By Michael Collier

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) LogoInvestors sentiment increased to 1 in 2018 Q2. Its up 0.67, from 0.33 in 2018Q1. It is positive, as 2 investors sold Oramed Pharmaceuticals Inc. shares while 2 reduced holdings. 2 funds opened positions while 2 raised stakes. 251,588 shares or 7.11% more from 234,885 shares in 2018Q1 were reported.
Royal Comml Bank Of Canada owns 1,500 shares. Citigroup holds 7,400 shares. Morgan Stanley stated it has 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). 10,700 were reported by Wells Fargo & Com Mn. 1,117 were accumulated by Bancshares Of America Corporation De. Blackrock reported 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Glenmede Trust Na owns 20,000 shares or 0% of their US portfolio. 21,200 are owned by Pnc Financial Service Group. Bank Of Montreal Can accumulated 2,600 shares or 0% of the stock. Jfs Wealth Advsrs Limited Company owns 500 shares or 0% of their US portfolio. Renaissance Limited Company holds 0% or 69,800 shares. Deutsche Bancorporation Ag has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Barclays Public Limited Company holds 0% or 41,186 shares in its portfolio.

Since July 10, 2018, it had 1 insider purchase, and 0 insider sales for $357 activity.

Analysts expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) to report $-0.28 EPS on December, 5.They anticipate $0.08 EPS change or 40.00 % from last quarter’s $-0.2 EPS. After having $-0.30 EPS previously, Oramed Pharmaceuticals Inc.’s analysts see -6.67 % EPS growth. The stock decreased 0.23% or $0.01 during the last trading session, reaching $4.25. About 4,287 shares traded. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has declined 43.28% since November 11, 2017 and is downtrending. It has underperformed by 58.90% the S&P500.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $73.79 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

Another recent and important Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news was published by Prnewswire.com which published an article titled: “Oramed to Present at the Tides Europe 2018 Conference” on November 05, 2018.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>